March 20th 2023
The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer
Poll: How Would You Treat a Patient With NSCLC and an EGFR Exon 20 Insertion Mutation?
March 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joel Neal, MD, PhD, discussed what options physicians would choose when treating a patient with non–small cell lung cancer who tested positive for an EGFR exon 20 insertion.
Read More
Pembrolizumab Misses Survival End Points in mCRPC/NSCLC
March 1st 2023The phase 3 KEYNOTE-641 of pembrolizumab, enzalutamide, and androgen deprivation therapy has been discontinued, and overall survival rates in the phase KEYNOTE-789 study of pembrolizumab, pemetrexed, platinum-based chemotherapy did not meet statistical significance.
Read More
FDA to Review BLA for Perioperative Pembrolizumab/Chemotherapy for Stage II-IIIB NSCLC
March 1st 2023With statistically significant and clinically meaningful event-free survival improvement in patients with stage II-IIIB Non–small cell lung cancer, could perioperative pembrolizumab in combination with chemotherapy become a new treatment option?
Read More
Key Updates in the Changing NSCLC Treatment Landscape
February 10th 2023In the third interview of this series, Edward B. Garon, MD, reviews the treatment landscape in non–small cell lung cancer, with a focus on immunotherapy and the recent approval of tremelimumab in combination with durvalumab and platinum-based chemotherapy.
Read More
Porter Reviews Chemoimmunotherapy Combination Data in NSCLC
February 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Jason Porter, MD, discussed the CheckMate 9LA and KEYNOTE-407 trials of chemotherapy combined with immunotherapy in patients with advanced squamous cell lung cancer.
Read More
The Importance of Molecular Testing Before Adjuvant Therapy for NSCLC
January 24th 2023During a Targeted Oncology case-based roundtable event, Edward S. Kim, MD, MBA, discussed adjuvant therapy options and the use of molecular testing in patients with earlier-stage non–small cell lung cancer. This is the first of 2 articles based on this event.
Read More
Potential Immunotherapy Use in Patients with mNSCLC and RET Alterations
A focused discussion on whether immunotherapy might be an effective treatment option for patients with RET-positive mNSCLC.
Watch
The panel reviews LIBRETTO-001 and ARROW safety data on selpercatinib and pralsetinib in RET fusion-positive mNSCLC, and share their clinical experience in adverse event (AE) management in patients who are receiving one of these therapies.
Watch
Selpercatinib and Pralsetinib for RET Fusion-Positive mNSCLC and Supporting Efficacy Data
Dr Piotrowska outlines the RET tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib, which are available for patients with RET fusion-positive mNSCLC, then Dr Neal follows with a discussion of supporting efficacy data from the LIBRETTO-001 and ARROW trials.
Watch
RET Fusion-Positive mNSCLC: Case 2 Presentation and Molecular Testing Strategies
Joel Neal, MD, presents a second case of a 67-year-old man with no smoking history who was diagnosed with RET-rearranged mNSCLC, while Michelle Shiller, DO, AP/CP, MGP, touches on molecular testing approaches in patients who are suspected of having a RET alteration.
Watch
Mobocertinib Treatment-Emergent EGFR Mutations and Subsequent Therapy Selection
Zosia Piotrowska, MD, explains how she might treat a patient with EGFR exon 20-mutated mNSCLC who develops an EGFR T790M mutation after mobocertinib treatment.
Watch
Eftilagimod Alpha Combination Demonstrates Durable Responses in Frontline NSCLC
January 18th 2023Updated findings from the TACTI-002 trial of pembrolizumab and eftilagimod alpha in non–small cell lung cancer were presented during the Society for Immunotherapy of Cancer 37th Annual Meeting & Pre-Conference.
Read More
First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
January 18th 2023Edward B. Garon, MD, Professor of Medicine, and Director of the Thoracic Oncology group at the David Geffen School of Medicine at UCLA, reviews key clinical trial data and explains the rationale of using combination IO therapies in the treatment of non-small cell lung cancer (NSCLC).
Read More
FDA Approves FoundationOne Companion Diagnostic to Entrectinib in NSCLC
January 6th 2023The FDA has approved the liquid biopsy next-generation sequencing-based test FoundationOne Liquid CDx in companion with entrectinib for patients with non–small cell lung cancer with a ROS1 mutation in their tumor.
Read More
Management of Adverse Events Following Mobocertinib and Strategies for Treatment Modification
Dr Neal outlines second-line targeted treatment selection for the patient case, while Lauren Welch, MSN, NP-C, AOCNP, shares her experience with managing the adverse effects of mobocertinib in patients with EGFR exon 20-mutated mNSCLC and comments on potential strategies for treatment modification.
Watch